Clearside Biomedical, Inc. (CLSD) financial statements (2020 and earlier)

Company profile

Business Address 900 NORTH POINT PARKWAY
ALPHARETTA, 30005
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:23413884
Cash and cash equivalents238935
Short-term investments 332849
Other undisclosed cash, cash equivalents, and short-term investments 0(0)(0)
Prepaid expense1210
Other current assets1000
Other undisclosed current assets (0)00
Total current assets:25433984
Noncurrent Assets
Operating lease, right-of-use asset1
Property, plant and equipment1110
Restricted cash and investments0000
Other noncurrent assets 000
Total noncurrent assets:2110
TOTAL ASSETS:27444085
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities410105
Accounts payable1753
Accrued liabilities3353
Deferred revenue5
Debt213 
Deferred rent credit 0
Deferred revenue and credits0 
Other liabilities  00
Total current liabilities:1110145
Noncurrent Liabilities
Long-term debt and lease obligation5958
Long-term debt, excluding current maturities4958
Operating lease, liability1
Liabilities, other than long-term debt 110
Deferred revenue and credits10
Deferred rent credit 1
Total noncurrent liabilities:51068
Total liabilities:16211913
Stockholders' equity
Stockholders' equity attributable to parent11242172
Common stock0000
Additional paid in capital249230146137
Accumulated other comprehensive loss  (0)(0)
Accumulated deficit(238)(207)(124)(65)
Total stockholders' equity:11242172
TOTAL LIABILITIES AND EQUITY:27444085

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
Revenue, net 1
Gross profit:20 1
Operating expenses(32)(83)(59)(26)
Other undisclosed operating income  0 
Operating loss:(30)(83)(58)(25)
Nonoperating income (expense)(0)0(1)(1)
Interest and debt expense(1)(1)(1)(0)
Loss before gain (loss) on sale of properties:(32)(84)(60)(26)
Other undisclosed net income11  
Net loss:(31)(83)(60)(26)
Other undisclosed net income attributable to parent  10
Net loss available to common stockholders, diluted:(31)(83)(59)(26)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
Net loss:(31)(83)(60)(26)
Other comprehensive income (loss)  0(0)
Comprehensive loss:(31)(83)(60)(26)
Other undisclosed comprehensive income, net of tax, attributable to parent  10
Comprehensive loss, net of tax, attributable to parent:(31)(83)(59)(26)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: